Clinical Trial: De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07748260) titled 'De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast' on July 02.

Brief Summary: High pathological complete response (pCR) rates are seen using different neoadjuvant chemotherapy schedules with trastuzumab and pertuzumab in HER2-positive stage II-III breast cancer patients. Total pCR rates in breast and axilla have been described as high as 64%, and with an even higher rate of >80% in patients with HER2-positive and hormone receptor (HR) negative tumors.

pCR is associated with better long-term outcomes in patients with HER2-positive breast cancer. Neoadjuvant treatment of HER2-positive breast cancer typ...